Key points from article :
Edifice Health, a Stanford University spin-out, has secured $12 million in funding to advance its mission of improving healthspan and addressing ageing-related diseases. The company focuses on systemic chronic inflammation, a root cause of conditions like cancer, cardiovascular disease, and neurodegenerative disorders. Using biomarkers developed from the Stanford 1,000 Immunomes Project and AI-driven predictive tools, Edifice has created metrics to measure inflammation and developed personalized supplements to enhance inflammatory health.
Chairman and CEO Wolfgang Daum emphasized the importance of identifying measurable biomarkers to improve diagnosis, prevention, and treatment of chronic diseases. The investment will enable Edifice to expand its scientific capabilities and launch consumer-focused products next year. These offerings will combine innovative inflammatory health technologies with supplements aimed at extending healthy ageing.
In collaboration with partners, Edifice also plans to explore pharmaceutical applications and integrate its solutions into food and beverage industries. This broad approach aims to revolutionize healthcare and promote longer, healthier lives.
